Serum and EDTA-plasma concentrations of complement activation products were measured using ELISA kits according to the manufacturers' instructions, with sample dilutions adjusted to fall within the linear range of standard curves. MicroVue™ EIA kits from Quidel Corporation (San Diego, USA) were used to measure C5a (cat #A025), sC5b-9 (cat #A029), Ba (cat #A033), Bb (cat #A027), and C4d (cat #A009). Hycult Biotech kits (Uden, NE) were used to measure FD (cat #HK343) and FH (cat #HK342). Serum levels of IL-6 were measured using the Simoa HD-1 platform (Quanterix Corporation, Billerica, USA), as previously reported [25 (link)]. Reported precision for each complement ELISA kit are listed as follows (analyte, coefficient of variation): C5a, ≤ 3.9%; sC5b-9, ≤ 6.8%; Ba, 2.3%; Bb, ≤ 4%; C4d, ≤ 9.7%. Precision characteristics were not available for FD and FH kits. All samples were tested in duplicate and only values with a CV of ≤ 15% were included in analyses.
Complement System Activation Profiling
Serum and EDTA-plasma concentrations of complement activation products were measured using ELISA kits according to the manufacturers' instructions, with sample dilutions adjusted to fall within the linear range of standard curves. MicroVue™ EIA kits from Quidel Corporation (San Diego, USA) were used to measure C5a (cat #A025), sC5b-9 (cat #A029), Ba (cat #A033), Bb (cat #A027), and C4d (cat #A009). Hycult Biotech kits (Uden, NE) were used to measure FD (cat #HK343) and FH (cat #HK342). Serum levels of IL-6 were measured using the Simoa HD-1 platform (Quanterix Corporation, Billerica, USA), as previously reported [25 (link)]. Reported precision for each complement ELISA kit are listed as follows (analyte, coefficient of variation): C5a, ≤ 3.9%; sC5b-9, ≤ 6.8%; Ba, 2.3%; Bb, ≤ 4%; C4d, ≤ 9.7%. Precision characteristics were not available for FD and FH kits. All samples were tested in duplicate and only values with a CV of ≤ 15% were included in analyses.
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : University of British Columbia, Spinal Cord Injury BC
Variable analysis
- None explicitly mentioned
- Complement activation via the CP, the LP (MBL-dependent), and the AP in the serum of participants
- Serum and EDTA-plasma concentrations of complement activation products (C5a, sC5b-9, Ba, Bb, C4d, FD, FH)
- Serum levels of IL-6
- All determinations were performed in duplicate
- Sample dilutions were adjusted to fall within the linear range of standard curves
- All samples were tested in duplicate and only values with a CV of ≤ 15% were included in analyses
- No positive or negative controls were explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!